Omniscient Neurotechnology (o8t) is a Sydney-based brain-mapping company that uses AI and machine learning to turn ordinary MRI scans into detailed maps of the brain's electrical networks, or connectomes. Its flagship FDA-cleared platform, Quicktome, gives neurosurgeons a patient-specific view of the pathways responsible for speech, movement and cognition before they operate, while its research platform, Infinitome, helps scientists study how diseases like Alzheimer's, epilepsy and schizophrenia disrupt brain connectivity. Founded in 2019 and led by CEO Stephen Scheeler, the company has raised roughly US$124 million to date and is expanding connectomics into stroke, movement disorders and brain-computer interfaces.
Cognito Therapeutics is a Cambridge, Massachusetts clinical-stage neurotechnology company spun out of MIT that develops non-invasive, wearable therapy for neurodegenerative disease. Its lead product, Spectris, delivers precise gamma-frequency light and sound stimulation through connected glasses and headphones to evoke gamma brain oscillations, with the goal of slowing cognitive and functional decline in Alzheimer's disease. Spectris AD holds FDA Breakthrough Device Designation and is being evaluated in the HOPE Study, described as the largest medical device trial focused solely on Alzheimer's disease.
Muse, made by Toronto-based Interaxon Inc., is a brain-sensing headband that turns clinical-grade EEG into a consumer wearable. First shipped in 2014, Muse reads your brainwaves and, through a companion app, gives real-time audio feedback to guide meditation, track sleep, and train focus. The company has since layered on fNIRS and SpO2 sensing (Muse S Athena, 2025) and an AI brain-health platform trained on more than a billion minutes of EEG data, positioning Muse at the intersection of consumer wellness and clinical neuroscience.
Circular Genomics is a San Diego biotechnology company turning circular RNA (circRNA) into a new class of blood-based biomarkers for brain health. Spun out of the University of New Mexico in 2021, the company uses brain-enriched circRNAs that cross the blood-brain barrier and stay stable in whole blood to detect and predict neurological and psychiatric conditions, from Alzheimer's disease to major depressive disorder. Its goal is to replace guesswork in brain care with measurable, actionable data, starting with early Alzheimer's detection and SSRI treatment-response testing for depression.
Elysium Health is a New York-based cellular health company that turns peer-reviewed aging research into consumer products. Founded in 2014 by entrepreneur Eric Marcotulli, operator Dan Alminana, and MIT aging biologist Leonard Guarente, it pairs a scientific advisory board stacked with Nobel laureates with a direct-to-consumer model. Its flagship supplement Basis raises NAD+ levels tied to cellular energy, and its Index test estimates biological age from a saliva sample using epigenetic methylation analysis.
Beacon Biosignals is a Boston-based neurotechnology company that pairs FDA-cleared wearable EEG hardware with AI to turn brain electrical activity - especially during sleep - into scalable, at-home neurodiagnostics. Its platform powers drug development, clinical trials, and precision medicine across neurology, psychiatry, and sleep medicine.